The effect of platelet-rich plasma on the fusion rate and clinical outcome of spinal fusion surgery: A systematic review and meta-analysis

Ying-feng Cai*, Tian-Zhao Tian*, Li-Ye Chen*, Bao-Xin Liu, Jian-Peng Zhou, Min Shi, Hao-Dong Liang

Department of Orthopaedics, The Affiliated TCM Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of China

* These authors contributed equally to this work.
* aldd911@163.com

Abstract

Background
Platelet-rich plasma (PRP) is widely used in many orthopedic surgeries and spinal disease treatments; however, the effect of PRP on spinal fusion remains controversial.

Questions/Purposes
To assess the fusion rate and clinical results of PRP compared with non-PRP administration in the treatment of spinal fusion with regard to decreasing pain and improving healing and function.

Patients and methods
Studies comparing PRP to non-PRP treatment with respect to the fusion rate and clinical outcome in patients who underwent spinal fusion surgery were included.

Result
Three randomized controlled trials (RCTs) and 7 prospective cohort studies were identified. The spinal fusion rate was not significantly different between the groups in all RCTs or cohort studies at the final follow-up. In comparison, PRP significantly reduced pain after surgery as evaluated in the RCT analysis and the complication rate did not differ significantly between the two groups.

Conclusion
According to the available studies, PRP does not contribute to the union rate, relieve pain or increase the complication rate in spinal fusion surgery. As clinical heterogeneity exists in these studies, further large, well-designed RCTs that focus on the standard assessment of PRP are needed.
Introduction

Spinal fusion is an effective treatment method for spinal diseases, such as disc herniation, spinal instability and degenerative spinal diseases. However, studies have reported 5%-43% non-union and pseudarthrosis after spinal fusion surgery [1, 2], which can lead to poor clinical outcomes and increase the economic burden of patients. Therefore, many strategies have been created to accelerate bone union [3, 4].

Treatment with platelet-rich plasma (PRP) is a promising strategy that uses a small amount of plasma containing a high concentration of platelets and osteoinductive autologous growth factors and has been reported to help the regeneration of bone and tissue. The additional platelets may substantially increase the concentration of growth factors at the site of injury and augment the natural healing process [5]. Studies have shown the efficacy of accelerating bone union and spinal fusion in vivo and in vitro. PRP has also been used in ligament reconstruction surgeries to enhance ligament and articular regeneration and simultaneously relieve pain. Animal and clinical studies have also suggested a positive effect of PRP [6–8].

With the increasing attention to and wide use of PRP in orthopedics, there is a growing debate regarding its clinical efficacy, especially in spinal surgery. Some randomized controlled trials (RCTs) have shown less favorable results for the fusion rate and pain score [8, 9], which were in contrast to the results of other studies. Given this uncertainty, we undertook a systematic review and meta-analysis of RCTs and cohort studies to assess the fusion rate and clinical results of PRP compared with non-PRP in the treatment of spinal fusion, with regard to decreasing pain and improving healing and function.

Methods

Eligibility criteria

Studies comparing PRP to non-PRP with respect to the fusion rate and clinical outcome in patients who underwent spinal fusion surgery were included. Inclusion criteria were defined before the search process, and are listed as follows: (1) patients with degenerative disc diseases, lumbar disc herniation, spinal instability and other spinal diseases who were scheduled for spinal fusion; (2) RCTs and cohort studies comparing PRP with non-PRP; and (3) primary outcomes that include fusion rate and adverse events related to PRP and the visual analog scale (VAS). The secondary outcomes included the clinical outcome assessed after surgery, such as the patient report Short Form 36 (SF-36) and the Oswestry Disability Index (ODI). Clinical trials without comparison groups or animal studies or laboratory research were excluded form our research.

Search strategy

The methods in this review were conducted in accordance with the Cochrane Collaboration criteria [10]. A comprehensive literature search of relevant RCTs and cohort studies involving both PRP and spinal fusion was performed in PubMed, Embase, and the Cochrane Library from database inception to April 2019. Database searching was performed using the following terms: “spinal fusion,” “spondylodesis,” “spinal arthrodesis,” “Lumbar arthrodesis,” “platelet-rich plasma,” “platelet gel,” “platelet fibrin,” “platelet glue,” and “PRP”. The full details of the search process are shown in S1 Table.

The main search was completed by the senior authors (YFC and LYC). Any discrepancy was identified by discussion with another investigator (HDL) who was not involved in the initial procedure. The reference lists of eligible studies and “related articles” featured in PubMed were also reviewed in our search. The ages of the patients and follow-up periods were not
restricted, and the publication language was limited to English. If more than one study was identified from the same population, data from the most recent or complete report of that study were extracted.

**Study selection and data extraction.** Two investigators (YFC, TZT) independently extracted the relevant data from each study using a predefined data extraction form listing the study characteristics, which included the first author’s name, publication year, country, study design, follow-up duration and outcome measurements for each study. Any disagreements were resolved by discussion or consensus with a third reviewer (BXL). Radiological fusion was defined as the absence of significant angular motion (no more than 2˚) on flexion and extension radiographs and evidence of bridging bone on computed tomography (CT) scans or plain graphs [11]. The fusion rate was calculated by the number of patients who achieved fusion divided by the total cohort. Complication rates were calculated on the basis of events related to surgery, such as pseudoarthrosis, infection, reoperation and seroma, according to previous studies [12, 13]. Specific complications, such as donor site pain, were not included in our analysis. The corresponding authors of the included RCTs were contacted to obtain any missing data when necessary.

**Outcome and methodological quality assessment.** The methodological quality and risk of bias of the included studies, including randomization, allocation concealment, blinding method, selective reporting, group similarity at baseline, incomplete outcome data, compliance, timing of outcome assessments, and intention-to-treat analysis, were separately assessed by two reviewers (YFC and BXL) using the Cochrane Collaboration tool [10]. All disparities between the two reviewers were resolved by consultation with another author (LYC). A quality assessment of observational studies was conducted in accordance with a modified version of the Newcastle-Ottawa Quality Assessment Scale (NOS) [14]. A maximum of two stars was given for comparability. We obtained 60% or more of the maximum number of stars as high-quality studies [14].

**Statistical analysis and data synthesis.** Pooled analyses were performed using Review Manager (RevMan Version 5.3., the Cochrane Collaboration, Oxford, UK). Risk ratios (RRs) with a 95% confidence interval (CI) were used to assess dichotomous outcomes. Continuous outcomes were expressed as the mean difference (MD) with 95% CI. Heterogeneity was assessed using the I^2 statistic. According to the Cochrane review guidelines, severe heterogeneity of I^2 ≥ 50% warrants the use of a random-effects model. Otherwise, a fixed-effects model should be used. I^2 ≥ 50% represented high heterogeneity. Subgroup analyses were performed according to different timepoints.

**Ethics statement.** The study was approved by the Ethics Committee of the Affiliated TCM Hospital of Guangzhou Medical University. This review was registered in PROSPERO: CRD 42019132218 (https://www.crd.york.ac.uk/PROSPERO/). The work was performed at the Affiliated TCM Hospital of Guangzhou Medical University.

**Patient and public involvement.** No patients or public parties were involved in this study.

**Results**

**Literature search**

We generated 136 relevant studies through a comprehensive search (Fig 1). After removing 84 complicated duplicate studies, 52 studies were retrieved. After screening the titles and abstracts of the remaining studies, 34 studies of the following types were excluded: in vivo or in vitro investigations (9), laboratory research (7), and studies on unrelated topics (3). We finally identified 18 potentially relevant studies. After careful full-text screening, the following publication
types were excluded: noncomparative trial (4), inappropriate intervention (2) and animal studies (2). Three RCTs and 7 cohort studies published from 2003 to 2019 involving 3 different PRP types and 566 participants were ultimately included in the present study. The characteristics of the included studies are presented in Table 1. The total sample sizes were 69 for the PRP group and 69 for the control group in the RCTs and 202 for the PRP group and 226 for the control group in the cohort studies. The populations of the included studies ranged from 35 to 107 participants. The follow-up durations ranged from 8 months to 10 years.

PRP is typically prepared from autologous whole blood through two centrifugation steps. First is a “separation” step, in which the red blood cells are separated out from the plasma and platelets through centrifugation. The plasma and platelet layers are then removed and a second centrifugation step, the “concentration” step, is performed to extract a platelet pellet [15]. The PRP preparation methods in the included studies varied (Table 2). Feiz-erfan and Sys et al. used the same platelet concentration system (DePuy Symphony system) [16]. Castro and Jenis et al. concentrated platelets through an ultrafiltration device. Hartmann et al. prepared PRP using a Biomet Gravitational Platelet Separation system. Three activation methods were measured in the included studies. Three studies used CaCl$_2$ and thrombin for activation, while four studies used thrombin or CaCl$_2$ only. Moreover, the activation method was not reported
in 2 studies. For the formulation of the PRP, most studies reported the formulation as a PRP gel. The eventual formulation reported by Jenis and Acebal et al. was a platelet-rich solution. Tsai et al. mixed the obtained platelets with fresh frozen plasma and a calcium chloride combination was then added to local fragmented laminectomy bone to finally obtain the platelet glue. All researches collected PRP from autologous whole blood in participants except Tsai et al., who obtained platelet concentrate from the blood bank. Acebal et al. reported that autologous platelet concentrate harvesting was performed by taking 100 cc blood, but they did not mention the preparation method. Castro and Jenis et al. collected 1 unit of whole blood from the patients. Kubota and Imagama et al. collected a total of 400 mL of whole blood from each patient, and then separated and centrifuged the sample to collected the plasma. Hartmann

| Study/year      | Type of study | Number of participants | Number of levels | Age (Mean), y | Gender (% Male) | Follow-up (Mean), m | Surgical Indications                                                                 | Surgical approach                     | Outcome assessment                                                                 |
|-----------------|---------------|------------------------|------------------|--------------|-----------------|-------------------|--------------------------------------------------------------------------------------|----------------------------------------|-----------------------------------------------------------------------------------|
| Feiz-erfan/2007 | RCT           | 25/25                  | 42/39            | 46.0/46.0    | NA              | 24/24             | cervical degenerative disease and herniated disc                                    | ACDFP                                  | SF-36; NDI; VAS; modified Prolo scale; fusion rate                                |
| Sys/2011        | RCT           | 19/19                  | 19/19            | 74.9/76      | 63/24           | 24/24             | lytic and degenerative spondylolisthesis, disc degeneration and herniated disc      | posterior lumbar interbody fusion      | VAS, ODI; SF-36; fusion rate; blood loss                                         |
| Kubota/2019     | RCT           | 25/25                  | Single:18/15; Two:7/10 | 65.1/65.3 | 60/56           | 24/24             | lumbar spinal stenosis with spondylolisthesis plus instability                     | posterolateral lumbar fusion           | VAS; fusion rate; duration for bone union; quantification of platelet count and growth factor concentrations |
| Gastro/2004     | Cohort study  | 22/62                  | Single:15/37; Two:7/25 | 47.0/49.0 | 27/34           | 34/41             | degenerative disc disease; stenosis; pseudoarthrosis; spondylolisthesis            | transforminal lumbar interbody fusion  | fusion rate; operative times; estimated blood loss; postoperative drainage; transfusion; length of hospitalization; arthrodesis rate; platelet counts; complications |
| Jenis/2006      | Cohort study  | 15/22                  | Single:5/12; Two:10/10 | 40.3/41.4 | 67/64           | 24.3/25.7         | degenerative disc disease and spondylolisthesis                                    | anterior-posterior interbody fusion    | SF-36; ODI; VAS; fusion rate                                                      |
| Tsai/2009       | Cohort study  | 34/33                  | 34/33            | 59.8/63.3    | 32/18           | 28.5/27.6         | spondylolisthesis                                                                  | posterolateral lumbar fusion           | fusion rate; postoperative drainage; clinical outcome (MacNab criteria)           |
| Hartmann/2009   | Cohort study  | 15/20                  | Single:7/11; Two:8/8; Three:0/1 | 43.7/39.8 | 67/65           | 8.33/12.5         | traumatic fracture of the lower thoracic or lumbar spine                           | posterior and anterior spinal fusion   | fusion rate; VAS                                                                  |
| Acebal-cortina/2011 | Cohort study | 67/40                  | Single:34/25; Two:33/12; Three:0/3 | 57.0/59.0 | 43/60           | 24/24             | lumbar degenerative pathologies                                                    | posterolateral lumbar fusion           | fusion rate;                                                                   |
| Imagama/2017    | Cohort study  | 29/29                  | 29/29            | 63.3/63.3    | 38/38           | 240/240           | degenerative lumbar disease                                                        | posterolateral lumbar fusion           | fused bone area; Japanese Association Score; Time Course of Bone Absorption; bone density; fusion rate |
| Rezende/2017    | Cohort study  | 20/20                  | NA               | 49.18        | NA              | 24/24             | hernia with instability; spondylolisthesis; hernia with stenosis                   | NA                                     | fusion rate;                                                                     |

SF-36: Short Form–36; RCT: randomized controlled trial; VAS: visual analog scale; ACDFP: anterior cervical discectomy with internal fixation and plating; ODI: Oswestry Disability Index; NDI: Neck Disability Index.

https://doi.org/10.1371/journal.pone.0243204.t001
et al. prepared PRP from 110 ml of patient blood. The final volume of PRP was not available in most studies. Only Kubota et al. reported that they finally generated 22 ml of PRP. Rezende et al. did not report the detailed preparation method or formulation of PRP [17].

Study characteristics and quality of evidence

Details of the bias assessment of RCTs and cohort studies are shown in Table 3. All included RCTs were performed at a single center. Kubota et al. reported random sequence generation defined as having a low risk of bias, while the remaining trials did not. All RCTs were defined as having a low risk of detection bias because the outcomes were assessed separately by professors who were blinded to the research. Incomplete outcome data were observed in one trial [9], as there was no detailed description of the two drop-outs. This factor was judged as having a high risk of attribution bias. A high risk of reporting bias was found in the study by Feizerfan et al., as no direct comparison of clinical outcomes was conducted between groups at all timepoints. For the prospective cohort study, the methodological quality of five studies [18–22] was considered to be high on the basis of the NOS (Table 3). The main deficiency of the Hartmann et al. study was reporting bias related to the control group that was drawn from different sources, with an insufficient description of the outcome assessment and a short follow-up.

Outcomes of the meta-analyses

Primary outcomes

Fusion rate. All of the included studies, which comprised 178 patients and 226 levels in RCTs and 388 participants and 408 levels in cohort studies, reported the fusion rate in spinal surgery. One study involved surgery on the cervical spine [16], and the other studies involved surgeries on the lumbar spine. The fusion rate was assessed at 3 months, 4 months, 6 months, 12 months, 24 months and 10 years postoperatively. Fusion was evaluated through CT in all studies, except four [16, 20, 23, 24], which were evaluated through X-ray imaging. Sys et al. reported that fusion was achieved in all but one patient from the control group, and no significant difference was found by CT scan between the two groups in interbody healing. Feizerfan et al. compared the fusion rate in patients with varied levels of surgery based on the levels of bony union and reported a higher fusion rate in the PRP group (18/30) than in the control group (12/25) at 6 and 12 weeks, but this difference was no longer apparent at one year. Kubota et al. assessed the bone union rate at two sites at each fusion level and showed a higher fusion rate in the PRP group than in the control group (93.7% vs 74.2%); the PRP group

Table 2. PRP formulation.

| Studies          | Preparation method                  | Activation method | Formulation     |
|------------------|-------------------------------------|-------------------|-----------------|
| Feiz-erfan et al.| DePuy Symphony system               | NA                | Platelet gel    |
| Sys et al.       | DePuy Symphony system               | CaCl₂ and thrombin| Platelet gel    |
| Kubota et al.    | Hitachi Koki, CR7B3                 | CaCl₂ and thrombin| Platelet gel    |
| Castro et al.    | Interpore Koki, CR7B3               | thrombin          | Platelet gel    |
| Jenis et al.     | Centrifugation and ultraconcentrator| thrombin          | Platelet gel    |
| Tsai et al.      | Platelet concentrate from the blood bank| CaCl₂ and thrombin | Platelet gel    |
| Hartmann et al.  | Biomet Gravitational Platelet Separation system | thrombin | Platelet gel    |
| Acebal et al.    | NA                                  | NA                | Solution        |
| Imagama et al.   | Kubota 9800 Centrifuge             | calcium gluconate and thrombin | NA        |
| Rezende et al.   | NA                                  | CaCl₂             | NA              |

https://doi.org/10.1371/journal.pone.0243204.t002
achieved a shorter time of bone union (7.8 ± 0.6 vs 9.8 ± 0.6 months). Data on the fusion rate and time needed for bony fusion in RCTs were not available for a pooled analysis because of the varied definitions and methods for evaluating fusion. A meta-analysis was performed in 6 cohort studies, as the study in which Castro et al. reported a fusion rate based on the fusion level was excluded from the present analysis. The pooled analysis did not show that PRP treatment was able to significantly increase the fusion rate in the final follow-up (RR = 0.96, 95% CI: 0.88–1.05, P = 0.11); however, there were no available data to perform a subgroup analysis evaluating the fusion rate at different timepoints postoperatively (Fig 2).

Table 3. Risk of bias in the included studies.

| Study            | Random sequence generation | Allocation concealment | Blinding of participants | Blinding of personnel | Blinding of outcome assessment | Incomplete outcome data | Selective reporting |
|------------------|----------------------------|------------------------|--------------------------|-----------------------|-------------------------------|-------------------------|---------------------|
| Feiz-erfan et al.| unclear                   | unclear                | low                      | low                   | low                           | low                     | high                |
| Sys et al.       | unclear                   | low                    | unclear                  | unclear               | low                           | high                    | low                 |
| Kubota et al.    | low                       | unclear                | low                      | low                   | low                           | low                     | low                 |

| Study            | Representiveness of the exposed cohort | Selection of the nonexposed cohort | Ascertainment of exposure | Demonstration outcome already | Comparability of cohorts | Assessment of outcome | Follow-up time | Adequacy of follow-up of cohorts |
|------------------|----------------------------------------|-------------------------------------|---------------------------|-------------------------------|-------------------------|----------------------|----------------|----------------------------------|
| Gastro et al.    | low                                    | low                                 | low                       | high                          | low                     | high                 | low             | low                              |
| Jenis et al.     | low                                    | low                                 | low                       | high                          | low                     | low                  | low             | low                              |
| Tsai et al.      | low                                    | low                                 | low                       | high                          | low                     | high                 | low             | low                              |
| Hartmann et al.  | low                                    | high                                | low                       | low                           | high                    | high                 | low             | high                              |
| Acebal et al.    | low                                    | low                                 | high                      | low                           | low                     | low                  | low             | low                              |
| Imagama et al    | low                                    | high                                | low                       | low                           | low                     | high                 | low             | low                              |
| Rezende et al.   | high                                   | high                                | low                       | high                          | low                     | high                 | low             | low                              |

Fig 2. Forest plot of the fusion rate in cohort studies.

![Forest plot of the fusion rate in cohort studies](https://doi.org/10.1371/journal.pone.0243204.g002)
VAS. All included RCTs assessed patients via the VAS; however, only two RCTs and two cohort studies compared the PRP group to the non-PRP group (Fig 3). The other study compared degenerative diseases with herniated disc diseases. The pooled analysis of RCTs showed that PRP relieved pain better than the control treatment, with a significant difference (SMD = -0.07, 95% CI: -0.91–1.06, P = 0.02). However, the pooled analysis of cohort studies suggested no significant difference between groups (SMD = -0.33, 95% CI: -1.00–0.35, P = 0.16).

Complications. Complications were varied and recorded in all of the included studies; such adverse events included pseudarthrosis, reoperation, infection, etc. No pseudarthrosis or other complications were reported in four studies [8, 19–21]. Sys et al. reported that transient radiculopathy occurred in one patient in the study group and two patients in the control group. Feiz-erfan et al. reported that a screw protruded minimally in two patients and that one patient died of cardiac disease. However, the details of the groups comprising these patients are not known. Jenis et al. reported 2 revisions, as one patient experienced vein injury and another experienced symptomatic pseudarthrosis. The complication rate was compared in only one study (by Castro et al.), and the results showed a lower complication rate in the study group than in the control group. These authors reported complications in 14 patients in the study group and 41 patients in the control group. Among these patients, 6 revisions in the control group were due to instrumentation malposition, and 5 revisions in the PRP group were due to pseudarthrosis. The other complications recorded in these studies were adjacent segment degeneration, arachnoiditis, intractable pain, dural tears, instrument malposition, instrument removal, infections and death. Meta-analyses were available for cohort studies (Fig 4), and the results suggested that the complication rate did not differ significantly between the two groups (RR = 1.19, 95% CI: 0.82–1.72, P = 0.38).

Secondary outcomes

Pseudarthrosis. Pseudarthrosis was reported in four studies. Assessment methods, including X-ray and CT, revealed that only one RCT [16] and three cohort studies reported comparisons of pseudarthrosis (Fig 5). The pooled analysis of cohort studies showed no significant difference between groups (RR = 1.64, 95% CI: 0.94–2.87, P = 0.25).
SF-36. Three studies assessed clinical outcomes based on SF-36 [9, 16, 22]. Feiz-erfan et al. compared the average score pre- and postoperatively, but there were no direct comparisons between groups. The overall mean score of SF-36 was increased at the 1-year and 2-year follow-up, and patients with herniated disc diseases had higher mean scores on the SF-36 than those with degenerative disc diseases. Both groups showed improvements in each domain of the SF-36 in the Sys et al. study. There were clinically important improvements in each domain (7.0 points) and statistically significant improvements in 6 domains; however, improvements in vitality and mental health in the PRP group were not statistically significant.

Publication bias. Publication bias was determined using funnel plots and Egger’s test. The funnel plots for publication bias using the fusion rate in the final follow-up suggest no obvious asymmetry, and the funnel plots indicated that the pooled results were not influenced by the publication bias (Fig 6). An Egger’s linear regression method suggested no statistically significant evidence of publication bias was observed (P = 0.701) (Fig 7).

Discussion

Increasing the fusion rate, improving pain release and decreasing complications were important in spine fusion surgery and were also the focus of many researchers. Recently, the use of PRP in spinal fusion surgery was investigated, and the results [8], which were not consistent with those of previous studies [9, 16], were promising. Several systematic reviews have
Fig 6. Funnel plot of publication bias.
https://doi.org/10.1371/journal.pone.0243204.g006

Fig 7. Egger’s publication bias plot.
https://doi.org/10.1371/journal.pone.0243204.g007
evaluated the effectiveness of PRP for spinal fusion. Elder et al. concluded that there is insufficient evidence to recommend the widespread use of PRP in spinal fusion surgery [15]. Park et al. reported that PRP might promote human spinal fusion if the platelet count or the concentration of growth factors in the PRP increases [25]. However, those studies included both animal and clinical studies and did not pool the available data for analysis. Our analysis aimed to include all available prospective studies evaluating the effectiveness and safety of PRP in spinal fusion, and moreover, we addressed whether PRP might increase the fusion rate and better relieve pain with fewer complications. No apparent publication bias was found according to the evaluation of the funnel plot and Egger’s test. To our knowledge, the present results derived from all available comparative data are the first to document the fusion rate, pain and complications between PRP and non-PRP in spinal fusion surgery.

PRP, which contains several growth factors, such as platelet-derived growth factor (PDGF) and transforming growth factor-β (TGF-β) [26, 27], is an autogenous source of growth factors with osteoinductive properties [28, 29]. As previously described, PRP is created by extracting platelets from whole blood and resuspending these factors in a small volume of plasma to form a concentrated platelet solution [5]. Although PRP is widely used in orthopedic, cardiovascular, and dental treatments, there is still a lack of a standard for PRP, including the extraction method, concentration level, activation method, whole blood volume needed and total volume after extraction. Mishra et al. proposed a system that classifies PRP by leukocyte content, platelet number, and activation into 4 types and 2 subtypes [30]. It is important to objectively assess the effectiveness of PRP. However, this system included only some of the factors that can influence PRP, and more details should be considered for classification.

In terms of fusion rate, our study included different methods to evaluate the fusion rate (i.e., CT and X-ray) at various timepoints (12 weeks, 4 months, 6 months, 1 year, 2 years and 10 years). CT scanning is more reliable for investigating bone union than X-ray. Even on flexion–extension films, it is difficult to assess fusion for several reasons: there is a difference in the range of motion of 7 to 14 in asymptomatic individuals, pain may inhibit motion, and the measurement of motion may be unreliable in the presence of pedicle-screw instrumentation [31]. Three of the included studies used only X-ray imaging to assess the fusion rate [16, 20, 23], and three studies used both CT and X-ray imaging for evaluation [8, 18, 22]. Jenis et al. used CT for 6-month evaluations and X-ray for 1- and 2-year evaluations postoperatively. CT was performed at 1 year after surgery for fusion assessment in the Tsai et al. study. These factors may increase the potential heterogeneity of the results. Pooled analysis of the RCTs or observational studies suggested that there was no significant difference between groups. As varied timepoints of fusion rate assessment were reported, we performed a subgroup analysis of RCTs based on different timepoints. The results at both 3 months and 12 months postsurgery showed no significant difference between groups. Interestingly, we discovered that PRP groups may have achieved faster fusion at 6 months after surgery than the control, although the difference was not significant, and only 2 RCTs reported the fusion rate at this timepoint. Other studies have also revealed a positive effect of PRP on accelerating fusion in a shorter time. Hartment et al. reported that the use of PRP provides faster fusion (8.33 vs. 12.5 months) and higher density values within the fusion mass for patients who sustained a traumatic fracture of the spine. Imagama et al. conducted a study of patients who underwent one-level lumbar fusion, and the local bone on the left side and the local bone treated with PRP on the right side were grafted. The results showed that the bone absorption assessed by CT was significantly lower on the PRP side at 3 and 6 months after surgery. A prospective cohort study performed by Tarantino et al. compared two sides at one-level fusion and demonstrated increased bone density using PRP and a heterologous cancellous block resulting in an enhanced fusion rate during the first 6 months after surgery [32]. According to these results,
we considered PRP to have a positive effect on the early fusion of the spine. However, because of the limited data, we could not conclude that PRP treatment would stimulate a shortened time of fusion.

Most of the studies included in our research had a follow-up of one and two years after surgery, which seems to be a short time. Only one study reported a result with a ten-year follow-up [21]. Although some researchers concluded that the fusion rate at one year after surgery did not differ significantly from the rate at two years postoperatively [16], one study considered the same fusion rate at one and two years postsurgery. As we do not know how long PRP can affect the bone and whether it can release growth factors continuously, studies with longer follow-up periods are needed to better assess the effectiveness and safety.

Clinical studies of PRP for low back pain patients have commonly shown that the intradiscal injection of PRP was effective in reducing back pain [33–35]. In our research, five of the included studies provided VAS scores, and all studies showed a significant decrease in pain scores after surgery compared with preoperative scores. However, the effect on relieving pain was comparable, regardless of PRP use. Four studies compared VAS scores between groups after surgery [8, 9, 19, 22]. Consistent with a previous review [5], compared with controls, PRP did not appear to reduce pain.

Regarding safety, the complication rate was consistent with a previous study. Therefore, using PRP in spinal fusion surgery did not increase side effects or complications. The complications reported in the included studies were infection, recurrent nerve palsy, screw protrusion, dural tears, revision and pseudarthrosis. The most common complication was pseudarthrosis. However, a study by Castro et al. reported a much higher complication rate than that in other studies, while the characteristics of the participants, surgical method and PRP concentration did not significantly differ between studies. The main reason for this result might be the lack of agreement on clear definitions of complications [12]. This disagreement makes statistical comparisons difficult. On the other hand, some complications might be ignored and may not be reported due to this lack of agreement. We believe it is meaningful to clinical practice to further assess the safety of PRP.

Although the surgical approaches, including anterior-posterior, posterior, and posterolateral approaches, the fusion method, as well as instrumented and noninstrumented fusion, varied in our included studies, which may be a potential factor influencing the PRP, some studies have concluded that different approaches in spine fusion did not affect the fusion rate [36, 37]. The preparation of PRP greatly varies and may be the cause for the differing biological activities reported among studies. Different PRP activation methods affect its physical form and can also change the release of bioactive molecules [38]. Moreover, as the methods of concentration differed in the various studies, the relationship between the effect of PRP on fusion and the fold-increase in platelets after concentration should be further assessed. A prospective cohort study suggested that no correlation between bone density and preoperative platelet count was observed [39]. However, an opposite result was shown in the Kubota et al. study, in which the average platelet count was 7.7 times higher and the growth factor concentrations were 50 times higher in PRP than in blood plasma, and these factors effectively shortened the time of bone union by approximately 2 months and promoted a higher fusion mass [8]. Another study showed that PRP had no stimulating effect if the PRP platelet count was five times that of peripheral blood [24]. Therefore, based on these limited data, whether there is a linear relationship between platelet count and bone fusion remains unknown. The bone grafts and extenders, including iliac bone, allograft bone and lamina, were also varied in the included studies. Eight of the included studies reported using autografts and two studies reported using allografts in their research. Kubota, Sys et al., Acebral-cortina et al., and Tsai et al. performed fusion using a local bone graft generated from the lamina in two groups. Imagama et al. used
milled lamina and spinous process bone as the bone graft in two groups. Hartmann et al. used a bone graft drawn out of the fractured vertebra. Castro et al. used an iliac crest bone graft in both groups. Rezende CF et al. reported using spinal process, laminae, and articular facets in two groups. Feiz-erfan et al. reported using allografts in both groups. Jenis et al. reported using an iliac crest bone graft in the control group and an allograft in the study group. These grafts and extenders may have substantially different effects on spinal fusion outcomes and have previously been shown to have varying effects on bone tissue engineering with PRP [40, 41]. However, the limited data could be analyzed to assess the potential effects of different bone grafts on fusion.

Many factors can influence the rate of spinal fusion, including diabetes mellitus, smoking habits, and alcohol intake, and these factors may have an impact on bone union [21, 42]. Only four of the included studies measured the characteristics of the smoking habits of the participants [9, 19, 21, 23], and this factor might have influenced our findings, as two recent studies have observed a significant association of pseudarthrosis development among smokers with a positive smoking status in anterior lumbar interbody fusion [2, 43].

Interestingly, substantial differences in surgical indications were observed among patients in different studies. Indications in most of the included studies were degenerative disease, herniated disc, spinal stenosis and spondyloytic spondylolisthesis, and all the surgical procedures were primary fusions. Patients with lumbar fracture were included in only one study [19], which suggests a positive effect of PRP on enhancing bony fusion. Another retrospective study involving 20 participants and 5 lumbar fractures suggested that PRP used with a cancellous bone substitute increases the rate of fusion and bone density. Feiz-erfan et al. reported that compared with a cohort of patients with disc herniation, patients with degenerative discs treated with a platelet gel demonstrated early fusion at the 12-week follow-up interval [16]. PRP was proven to have a positive effect on tissue and bone healing [44, 45]. It was speculated that the more extensive bone removal associated with the exposure of the cancellous material needed for decompression in the patients with degenerative disease afforded a better substrate for the platelet concentrate effect [16]. However, limited data were available to further evaluate which surgical indication was suitable for using PRP. Future studies should focus on the effects of PRP for different surgical indications.

Strengths and limitations
The present results derived from all the available prospective comparative data are the first to document the differences in the postoperative fusion rate, pain release, and complications between PRP and non-PRP treatments in spine fusion. Our study has several limitations. First, most of the included studies had low methodological quality. Only 3 RCTs and 7 observational studies with a small sample size were included, publication bias tests might be underpowered to detect the significance, and sample size heterogeneities might have biased the meta-analysis. Second, a standard concentration method, concentration, volume and activation of PRP, which were not consistent in the included studies, was lacking and may have increased the potential bias of the pooled analysis results. Third, in addition to the different surgical indications, such as spinal fracture, degenerated discs, spinal stenosis, and spinal instability, which were included in the present study, other parameters, such as the surgical approach, the graft and extender, rehabilitation program, and smoking habits, which may influence bone union progress after surgery, varied in the studies; previous studies noted that these factors were important for the prognosis of spine fusion. Fourth, the method of assessing fusion after surgery was not consistent, as some studies were assessed by plain radiographs while other studies were assessed by CT. Moreover, although the details of the complications were measured in
some of the included studies, the details of the complications in other studies remain unknown, and because of these limited data, we only evaluated complication rates and pseudarthrosis, which were measured in the included studies. Despite these limitations, the present systematic review and meta-analysis demonstrated that using PRP in spine fusion might accelerate early bone union and reduce pain but may not increase the fusion rate or complication rate.

Conclusion
In conclusion, PRP used in spinal fusion surgery increases neither the fusion rates, clinical outcome nor complication rates. However, this treatment might accelerate early bone union postoperatively. Additionally, PRP might increase the fusion rate of patients with spinal fractures. Therefore, based on cost effectiveness, regular use of PRP should not be considered for spinal fusion surgery. However, because only a few RCTs with small sample sizes and varied PRP preparations were included in the present study, more high-quality RCTs are needed to further evaluate the effect of PRP and the diseases appropriate for its use.

Supporting information
S1 Checklist. PRISMA 2009 checklist.
(DOC)

S1 Table. Search strategies in Pubmed.
(DOC)

Acknowledgments
We thank American Journal Experts for linguistic assistance during the preparation of this manuscript.

Author Contributions
Conceptualization: Ying-feng Cai, Hao-Dong Liang.
Data curation: Tian-Zhao Tian.
Formal analysis: Tian-Zhao Tian.
Funding acquisition: Ying-feng Cai.
Investigation: Li-Ye Chen.
Methodology: Li-Ye Chen, Jian-Peng Zhou.
Software: Min Shi.
Supervision: Bao-Xin Liu.
Validation: Bao-Xin Liu, Jian-Peng Zhou.
Visualization: Jian-Peng Zhou.
Writing – original draft: Ying-feng Cai.
Writing – review & editing: Hao-Dong Liang.
References

1. Woods KR, Billys JB, Hynes RA. Technical description of oblique lateral interbody fusion at L1-L5 (OLIF25) and at L5-S1 (OLIF51) and evaluation of complication and fusion rates. SPINE J. 2017 2017-04-01; 17(4):545–53. https://doi.org/10.1016/j.spinee.2016.10.026 PMID: 27884744

2. Phan K, Fadhil M, Chang N, Giang G, Gragnaniello C, Mobbs RJ. Effect of Smoking Status on Successful Arthrodesis, Clinical Outcome, and Complications After Anterior Lumbar Interbody Fusion (ALIF). WORLD NEUROSURG. 2018 2018-02-01; 110:e998–1003. https://doi.org/10.1016/j.wneu.2017.11.157 PMID: 2923523

3. Chen L, Yang H, Tang T. Cage migration in spondylolisthesis treated with posterior lumbar interbody fusion using BAK cages. Spine (Phila Pa 1976). 2005 2005-10-01; 30(19):2171–5. https://doi.org/10.1097/01.brs.0000180402.50500.5b PMID: 16205342

4. Carragee EJ, Mitsunaga KA, Hurwitz EL, Scudieri GJ. Retrograde ejaculation after anterior lumbar interbody fusion using rhBMP-2: a cohort controlled study. SPINE J. 2011 2011-06-01; 11(6):511–6. https://doi.org/10.1016/j.spinee.2011.02.013 PMID: 21612985

5. Sheth U, Simunovic N, Klein G, Fu F, Einhorn TA, Schenkel SL, et al. Efficacy of autologous platelet-rich plasma use for orthopaedic indications: a meta-analysis. J BONE JOINT SURG AM. 2012 2012-02-15; 94(4):298–307. https://doi.org/10.2106/JBJS.K.00154 PMID: 2241606

6. Kamoda H, Ohtori S, Ishikawa T, Miyagi M, Arai G, Suzuki M, et al. The effect of platelet-rich plasma on posterolateral lumbar fusion in a rat model. J BONE JOINT SURG AM. 2013 2013-06-19; 95(12):1109–16. https://doi.org/10.2106/JBJS.L.00320 PMID: 23783208

7. Kamoda H, Yamashita M, Ishikawa T, Miyagi M, Arai G, Suzuki M, et al. Platelet-rich plasma combined with hydroxyapatite for lumbar interbody fusion promoted bone formation and decreased an inflammatory pain neuropeptide in rats. Spine (Phila Pa 1976). 2012 2012-09-15; 37(20):1727–33. https://doi.org/10.1097/BRS.0b013e31825567b7 PMID: 22433505

8. Kubota G, Kamoda H, Orita S, Yamauchi K, Sakuma Y, Oikawa Y, et al. Platelet-rich plasma combined with hydroxyapatite for lumbar interbody fusion in a rat model. J BONE JOINT SURG AM. 2013 2013-06-19; 95(12):1109–16. https://doi.org/10.2106/JBJS.L.00320 PMID: 23783208

9. Kamoda H, Ohtori S, Ishikawa T, Miyagi M, Arai G, Suzuki M, et al. Platelet-rich plasma combined with hydroxyapatite for lumbar interbody fusion promoted bone formation and decreased an inflammatory pain neuropeptide in rats. Spine (Phila Pa 1976). 2012 2012-09-15; 37(20):1727–33. https://doi.org/10.1097/BRS.0b013e31825567b7 PMID: 22433505

10. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomized trials. BMJ. 2011 2011-10-18; 343:d5928. https://doi.org/10.1136/bmj.d5928 PMID: 21744284

11. Administration UFAD. Guidance for Industry and/or FDA staff: guidance document for the preparation of IDEs for spinal systems [Internet]. Silver Spring: US Food and Drug Administration; 2000 [cited 2015 Apr 21].

12. Fritzell P, Hagg O, Nordwall A. Complications in lumbar fusion surgery for chronic low back pain: comparison of three surgical techniques used in a prospective randomized study. A report from the Swedish Lumbar Spine Study Group. EUR SPINE J. 2003 2003-04-01; 12(2):178–89. https://doi.org/10.1007/s00586-003-0493-8 PMID: 12709856

13. Villavicencio AT, Burneikeine S, Bulsara KR, Thramann JJ. Perioperative complications in transforaminal lumbar interbody fusion versus anterior-posterior reconstruction for lumbar disc degeneration and instability. J SPINAL DISORD TECH. 2006 2006-04-01; 19(2):92–7. https://doi.org/10.1079/0707/01.bsd.000185277.14484.4e PMID: 16760781

14. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. EUR J EPIDEM.OL. 2010 2010-09-01; 25(9):603–5. https://doi.org/10.1007/s10564-010-9491-z PMID: 20652370

15. Elder BD, Holmes C, Goodwin CR, Lo SF, Puvanesarajah V, Kosztowski TA, et al. A systematic assessment of the use of platelet-rich plasma in spinal fusion. ANN BIOMED ENG. 2015 2015-05-01; 43(5):1057–70. https://doi.org/10.1007/s10439-015-1300-0 PMID: 25794962

16. Feiz-Erhan I, Harrigan M, Sonntag VK, Harrington TR. Effect of autologous platelet gel on early and late graft fusion in anterior cervical spine surgery. J Neurosurg Spine. 2007 2007-11-01; 7(5):496–502. https://doi.org/10.3171/SPI-07/11/496 PMID: 17977190

17. Rezende CF, Azevedo DP, Luorenco RB, Duarte JF, Cardoso IM, Jacob JC. Evaluation of the effectiveness of platelet-rich plasma in the bone consolidation of patients submitted to lumbar arthrosis. Rev Bras Ortop. 2017 2017-11-01; 52(6):693–8. https://doi.org/10.1016/j.rboe.2017.10.006 PMID: 29234653
18. Tsai CH, Hsu HC, Chen YJ, Lin MJ, Chen HT. Using the growth factors-enriched platelet glue in spinal fusion and its efficiency. J SPINAL DISORD TECH. 2009 2009-06-01; 22(4):246–50. https://doi.org/10.1097/BSD.0b013e3181753a2e PMID: 19494743

19. Hartmann EK, Heintel T, Morrison RH, Weckbach A. Influence of platelet-rich plasma on the anterior fusion in spinal injuries: a qualitative and quantitative analysis using computer tomography. Arch Orthop Trauma Surg. [2010 2010-07-01; 130(7):909–14]. https://doi.org/10.1007/s00402-009-1015-5 PMID: 19498805

20. Acebal-Cortina G, Suarez-Suarex MA, Garcia-Menendez C, Moro-Barrero L, Iglesias-Colao R, Torres-Perez E. Evaluation of autologous platelet concentrate for intertransverse lumbar fusion. EUR SPINE J. 2011 2011-08-01; 20 Suppl 3:361–6. https://doi.org/10.1007/s00586-011-1015-5 PMID: 21786039

21. Imagama S, Ando K, Kobayashi K, Ishikawa Y, Nakamura H, Hida T, et al. Efficacy of Early Fusion With Local Bone Graft and Platelet-Rich Plasma in Lumbar Spinal Fusion Surgery Followed Over 10 Years. Global Spine J. 2017 2017-12-01; 7(6):749–55. https://doi.org/10.1177/2192568217696690 PMID: 29238638

22. Jenis LG, Banco RJ, Kwon B. A prospective study of Autologous Growth Factors (AGF) in lumbar interbody fusion. SPINE J. 2006 2006-01-01; 6(1):14–20. https://doi.org/10.1016/j.spinee.2005.08.014 PMID: 16413442

23. Castro FJ. Role of activated growth factors in lumbar spinal fusions. J SPINAL DISORD TECH. 2004 2004-10-01; 17(5):380–4. https://doi.org/10.1097/01.bsd.0000110342.54707.19 PMID: 15385877

24. Hee HT, Majd ME, Holt RT, Myers L. Do autologous growth factors enhance transforminal lumbar interbody fusion? EUR SPINE J. 2003 2003-08-01; 12(4):400–7. https://doi.org/10.1007/s00586-003-0548-5 PMID: 12761691

25. Park MS, Moon SH, Kim TH, Oh JK, Yoon WY, Chang HG. Platelet-rich plasma for the spinal fusion. J Orthop Surg (Hong Kong). 2018 2018-01-01; 26(1):61441606. https://doi.org/10.1177/2309499018755772 PMID: 29415616

26. Canalis E, McCarthy TL, Centrella M. Effects of platelet-derived growth factor on bone formation in vitro. J CELL PHYSIO L. 1989 1989-09-01; 140(3):530–7. https://doi.org/10.1002/jcp.1041400319 PMID: 277891

27. Okuda K, Kawase T, Momose M, Murata M, Saito Y, Suzuki H, et al. Platelet-rich plasma contains high levels of platelet-derived growth factor and transforming growth factor-beta and modulates the proliferatation of periodontally related cells in vitro. J PERIODONTOL. 2003 2003-06-01; 74(6):849–57. https://doi.org/10.1902/jop.2003.74.6.849 PMID: 12886996

28. Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR. Platelet-rich plasma: Growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998 1998-06-01; 85(6):639–46. https://doi.org/10.1016/s1079-2104(98)90029-4 PMID: 9638695

29. Gruber R, Varga F, Fischer MB, Watzek G. Platelets stimulate proliferation of bone cells: involvement of platelet-derived growth factor, microparticles and membranes. Clin Oral Implants Res. 2002 2002-12-01; 13(5):529–35. https://doi.org/10.1034/j.1600-0501.2002.130515.x PMID: 12433131

30. Mishra A, Harmon K, Woodall J, Vieira A. Sports medicine applications of platelet rich plasma. Curr Pharm Biotechnol. 2012 2012-06-01; 13(7):1185–95. https://doi.org/10.2174/138920112800624283 PMID: 21740373

31. McAlee PC. Interbody fusion cages in reconstructive operations on the spine. J BONE JOINT SURG AM. 1999 1999-06-01; 81(6):859–80. https://doi.org/10.2106/00004623-199906000-00014 PMID: 10391552

32. Tarantino R, Donnarumma P, Mancarella C, Rullo M, Ferrazza G, Barrella G, et al. Posterolateral arthrodesis in lumbar spine surgery using autologous platelet-rich plasma and cancellous bone substitute: an osteoinductive and osteoconductive effect. Global Spine J. 2014 2014-06-01; 4(3):137–42. https://doi.org/10.1055/s-0034-1376157 PMID: 25083353

33. Monfett M, Harrison J, Boechie-Adjei K, Lutz G. Intradiscal platelet-rich plasma (PRP) injections for discogenic low back pain: an update. INT ORTHOP. 2016 2016-06-01; 40(6):1321–8. https://doi.org/10.1007/s00264-016-3178-3 PMID: 27073034

34. Lutz GE. Increased Nuclear T2 Signal Intensity and Improved Function and Pain in a Patient One Year After an Intradiscal Platelet-Rich Plasma Injection. PAIN MED. 2017 2017-06-01; 18(6):1197–9. https://doi.org/10.1093/pm/pnw299 PMID: 28339718

35. Aufiero D, Vincent H, Sampson S, Bodor M. Regenerative injection treatment in the spine: review and case series with platelet rich plasma. J Stem Cells Res. Rev & Rep. 2015; 2(1):1019.

36. Lee CS, Hwang CJ, Lee DH, Kim YT, Lee HS. Fusion rates of instrumented lumbar spinal arthrodesis according to surgical approach: a systematic review of randomized trials. Clin Orthop Surg. 2011 2011-03-01; 3(1):39–47. https://doi.org/10.4055/cios.2011.3.1.39 PMID: 21359477
37. Madan SS, Boeree NR. Comparison of instrumented anterior interbody fusion with instrumented circumferential lumbar fusion. EUR SPINE J. 2003 2003-12-01; 12(6):567–75. https://doi.org/10.1007/s00586-002-0516-5 PMID: 14673717

38. Cavallo C, Roffi A, Grigolo B, Mariani E, Pratelli L, Merli G, et al. Platelet-Rich Plasma: The Choice of Activation Method Affects the Release of Bioactive Molecules. BIOMED RES INT. 2016 2016-01-20; 2016:6591717. https://doi.org/10.1155/2016/6591717 PMID: 27672658

39. Tarantino R, Donnarumma P, Mancarella C, Rullo M, Ferrazza G, Barrella G, et al. Posterolateral arthrodesis in lumbar spine surgery using autologous platelet-rich plasma and cancellous bone substitute: an osteoinductive and osteoconductive effect. Global Spine J. 2014 2014-08-01; 4(3):137–42. https://doi.org/10.1055/s-0034-1376157 PMID: 25083353

40. Girardi FP, Cammisa FJ. The effect of bone graft extenders to enhance the performance of iliac crest bone grafts in instrumented lumbar spine fusion. ORTHOPEDICS. 2003 2003-05-01; 26(5 Suppl): s545–8. PMID: 12755222

41. Chen WJ, Tsai TT, Chen LH, Niu CC, Lai PL, Fu TS, et al. The fusion rate of calcium sulfate with local autograft bone compared with autologous iliac bone graft for instrumented short-segment spinal fusion. Spine (Phil Pa 1976). 2005 2005-10-15; 30(20):2293–7. https://doi.org/10.1097/01.brs.0000182087.35335.05 PMID: 16227892

42. Manzur M, Virk SS, Jivanelli B, Vaishnav AS, McAnany SJ, Albert TJ, et al. The rate of fusion for stand-alone anterior lumbar interbody fusion: a systematic review. SPINE J. 2019 2019-03-11. https://doi.org/10.1016/j.spinee.2019.03.001 PMID: 30872148

43. Kalb S, Perez-Orribo L, Kalani MY, Snyder LA, Martirosyan NL, Burns K, et al. The Influence of Common Medical Conditions on the Outcome of Anterior Lumbar Interbody Fusion. CLIN SPINE SURG. 2016 2016-08-01; 29(7):285–90. https://doi.org/10.1097/BSD.0b013e31827e4c85 PMID: 23274399

44. Lopez-Vidriero E, Goulding KA, Simon DA, Sanchez M, Johnson DH. The use of platelet-rich plasma in arthroscopy and sports medicine: optimizing the healing environment. ARTHROSCOPY. 2010 2010-02-01; 26(2):269–78. https://doi.org/10.1016/j.arthro.2009.11.015 PMID: 20141991

45. Anitua E, Andia I, Ardanaz B, Nurden P, Nurden AT. Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost. 2004 2004-01-01; 91(1):4–15. https://doi.org/10.1160/TH03-07-0440 PMID: 14691563